NALIRIFOX Improves OS in Pancreatic Cancer
NALIRIFOX improved overall survival and progression-free survival in patients with metastatic pancreatic ductal adenocarcinoma.
NALIRIFOX Improves Survival vs Nab-Paclitaxel/Gemcitabine in mPDAC
Zev A. Wainberg, MD, discusses recent findings from the NAPOLI 3 trial which were presented at the 2023 Gastrointestinal Cancers Symposium.
2 Clarke Drive Cranbury, NJ 08512